74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Syndax Pharmaceuticals Inc
Closed
SectorHealthcare
13.29 2.23
Overview
Share price change
24h
Min
12.65
Max
13.34
Income | -10M -94M |
|---|---|
Sales | -4.8M 7.7M |
EPS | -1.1 |
Profit margin | -1,226.159 |
Employees | 270 |
EBITDA | -5.3M -89M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +163.08% upside |
Next Earnings | 7 May 2025 |
|---|
Market Cap | -295M 1B |
|---|---|
Previous open | 11.06 |
Previous close | 13.29 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Syndax Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Syndax Pharmaceuticals Inc Forecast
Price Target
By TipRanks
163.08% upside
12 Months Forecast
Average 34.2 USD 163.08%
High 51 USD
Low 16 USD
Based on 12 Wall Street analysts offering 12 month price targets forSyndax Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
